98 results about "Akkermansia" patented technology

The invention relates to the technical field of microorganisms, in particular to a culture medium and a method for culturing Ackermania muciniphila for activating Amuc-1260 by using lambda-carrageenan as a carbon source, according to the culture method, the lambda-carrageenan is used for replacing a traditional carbon source, thallus growth and proliferation can be remarkably promoted, the effect is optimal under the condition of 2.00 g / L, and the culture cost is low. Compared with the conventional carbon source (glucose), the carbon source is improved by 92.91%. Further research finds that the lambda-carrageenan can induce the Akk bacteria to up-regulate the expression of glycoside hydrolase such as Amuc-1260 and enhance the activity of pathways such as glycosaminoglycan degradation, amino acid metabolism and insulin signals, so that the metabolic adaptability and energy utilization efficiency of the bacteria are improved. Meanwhile, the Akk bacteria secrete more functional short-chain fatty acids such as acetic acid, propionic acid and the like under the condition, and have the effects of regulating intestinal health and maintaining metabolic homeostasis. The invention provides a new theoretical basis and technical support for large-scale culture of Akk bacteria and development of a metabiotic product.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

This invention belongs to the field of anti-allergy functional food technology, specifically relating to an anti-allergy composition containing inactivated Akkermansia myxophilus. Existing anti-allergy drugs have side effects. The composition of this invention contains inactivated Akkermansia myxophilus, quercetin, vitamin C, and zinc. This invention can improve allergic rhinitis, alleviate eczema symptoms, and improve allergic constitution by regulating immune balance and inhibiting histamine release. The composition of this invention is stable at room temperature and can be formulated into powder or chewable tablets.

The invention belongs to the technical field of microorganisms, and discloses a new application of ackermania martensii and a new strain Amass-2. The strain is safe, has no toxic factors, and has the functions of reducing cholesterol, inhibiting fat synthesis and reducing body weight.

The invention belongs to the field of microorganisms and medicine health care, and relates to an ackermania muciniphila strain and application thereof, the preservation number of the ackermania muciniphila strain is CGMCC (China General Microbiological Culture Collection Center) No.34370, and a 16SrDNA (Deoxyribose Nucleic Acid) sequence of the ackermania muciniphila strain has 93% similarity with a sequence shown as SEQ ID NO: 1. The new ackermania muciniphila strain (AKKBC300) is separated from a healthy human body and has good safety; good tolerance to low pH value and bile salt is shown in vitro, and it is indicated that the compound can reach the intestinal tract through the upper digestive tract and play a role; according to the present invention, genomics analysis results prove that the bacterial strain contains the gene Akkermansia BC00573 with high homology with the known probiotic functional protein Amuc1100, such that the molecular basis is provided;

The present application relates to the field of microorganisms, in particular to a mucinophilic Akkermansia strain and application thereof, the mucinophilic Akkermansia has a preservation number of CCTCC NO: M 20241304.The mucinophilic Akkermansia AKK-86 of the present application has good effects of promoting iron absorption, improving iron metabolism, and relieving intestinal inflammation.In addition, the mucinophilic Akkermansia of the present application can also promote the production of GLP-1, and has potential application in reducing blood sugar and weight loss products.

This invention belongs to the field of anti-aging functional food technology, specifically relating to an anti-aging and longevity composition containing inactivated Akkermansia myxophilus. Existing anti-aging products are mostly single-ingredient products. The composition of this invention contains inactivated Akkermansia myxophilus, NMN, coenzyme Q10, resveratrol, and astaxanthin. This invention achieves the effects of delaying aging, improving muscle strength, and enhancing cognitive function by repairing the intestinal barrier, increasing NAD+ levels, and activating longevity pathways. The composition of this invention is stable at room temperature and can be formulated into capsules or powder.

The invention relates to an application of inactivated ackermania muciniphila Akk09 in preparation of a postbiotic preparation for controlling body weight and improving obesity. The preservation number of the ackermania muciniphila Akk09 is CCTCC (China Center For Type Culture Collection) NO: M 20242401. According to the present invention, the new use of the Ackermania muciniphila Akk09 is developed, the research basis is provided for the wide application of the Ackermania muciniphila Akk09, the brand new strategy for controlling body weight and improving obesity is developed, the inactivated Ackermania muciniphila Akk09 strain has significant effects on controlling body weight and improving obesity, and the inactivated Ackermania muciniphila Akk09 strain has significant application prospects. The Ackermania muciniphila Akk09 strain is a probiotic, the safety of the product is high, and the resistance is not easy to generate.

The application belongs to the field of biological detection, and particularly relates to a specific monoclonal antibody of an AKK bacterial efficacy protein Amuc_1100, a kit, a detection method and application thereof. The antibody pair is 3E10 and 2F7 monoclonal antibodies, the heavy chain and light chain variable region amino acid sequences of 3E10 are SEQ ID NO. 2 and SEQ ID NO. 4, and the heavy chain and light chain variable region amino acid sequences of 2F7 are SEQ ID NO. 6 and SEQ ID NO. 8. The antibody pair has high specificity and high affinity, a colloidal gold rapid detection kit and a double antibody sandwich ELISA quantitative detection kit based on the antibody pair realize rapid screening and accurate quantification of the Amuc_1100 protein, have good linearity, high precision and excellent accuracy, and can be used for detection of the protein in mucoid Akkermansia and quality control and activity evaluation of related probiotic preparations, thereby providing key technical support for related basic research and industrial application.

The application discloses a kind of improvement Akkermansia muciniphila The application discloses a starch-based feed for improving bacterial abundance, and belongs to the technical field of functional food. Experimental results show that the starch-based feed can significantly reverse the bacterial flora disorder of mice: PCoA analysis shows that it can restore the overall structure of the disordered bacterial flora to a healthy state; specifically, it improves the ratio of disordered Firmicutes / Bacteroidetes, promotes the proliferation of beneficial bacteria Akkermansia muciniphila, and inhibits the growth of conditional pathogenic bacteria, and the regulatory effect shows a dose-dependent manner. Therefore, the modified starch-based feed is a potential functional food raw material for regulating intestinal flora.

A pharmaceutical composition, a food composition, and a cosmetic composition for preventing or treating alopecia, and their uses are disclosed. The compositions contain, as an active ingredient, an Akkermansia sp. strain, vesicles of the strain, a proteome and metabolome of the strain, a culture of the strain, a lysate of the strain, an extract of the strain, an extract of the culture, or an extract of the lysate. The compositions for preventing or treating alopecia are safe for the human body, have no side effects, and have excellent effects of combating alopecia and promoting hair growth.

The application discloses application of pinoresinol diglucoside in increasing short-chain fatty acids in the postmenopausal intestinal tract and relieving postmenopausal intestinal inflammation, and belongs to the medical field. The pinoresinol diglucoside can regulate the abundance of Akkermansia, another branch bacteria, parabacteroides, rumenococcus and other genera in the intestinal tract, promote the expression of short-chain fatty acids in the postmenopausal intestinal tract, and then relieve postmenopausal intestinal inflammation and osteoporosis. The application opens up a new clinical approach for the treatment of postmenopausal women and diseases related to intestinal flora disorder.

The application belongs to the technical field of kidney disease differential diagnosis, and particularly relates to a microbial gene marker for differentiating diabetic nephropathy and membranous nephropathy and application thereof. The application provides sufficient evidence for the differentiation and treatment of clinical diagnosis of diabetic nephropathy and pathological diagnosis of membranous nephropathy based on four microbial markers of Blautia, Akkermansia, Sphingomonas and Granulicatella.

This invention belongs to the field of functional food technology, specifically relating to a hepatoprotective and hangover-relieving composition containing inactivated Akkermansia myxophilus. Existing hangover remedies mostly rely on a single mechanism, lacking multi-target synergy. The composition of this invention comprises inactivated Akkermansia myxophilus, hepatoprotective active ingredients, and components that promote alcohol metabolism. Through a triple synergistic effect of intestinal repair, liver protection, and accelerated alcohol metabolism, the composition of this invention can achieve the effects of liver protection, hangover relief, and prevention or relief of hangover symptoms. The composition of this invention is stable at room temperature and can be formulated into capsules, tablets, or powder.

The present application relates to a kind of probiotic oil agent for improving non-alcoholic fatty liver disease, preparation method and application, the probiotic oil agent includes active ingredient A and active ingredient B, the active ingredient A is mucinophilic Akkermansia Akk11, and the preservation number is CCTCC NO:M2024119;The active ingredient B is Omega-3 fatty acid.The present application is combined with mucinophilic Akkermansia Akk11 and Omega-3 fatty acid, and is prepared into oil agent, and the improvement of NAFLD symptom can play the coordinated synergistic effect, can be used for the prevention and treatment of NAFLD.

This invention belongs to the field of traditional Chinese medicine technology, and provides the application of Scutellaria baicalensis leaf aqueous extract in the preparation of drugs for improving or treating inflammatory bowel disease (IBD) with depression. The Scutellaria baicalensis leaf aqueous extract improves IBD with depression by increasing the abundance of Akkermansia myxophilus (AKK) bacteria, restoring disordered deoxycholic acid metabolism. The extract increases the abundance of AKK bacteria in the intestine, increases the content of deoxycholic acid (DCA) in the intestine, regulates Th17 / Treg homeostasis, reduces intestinal inflammation, maintains intestinal barrier integrity, reduces the entry of pro-inflammatory factors into the bloodstream and across the blood-brain barrier into the hippocampus, inhibits neuroinflammation, and improves depression. Scutellaria baicalensis leaves can improve IBD with depression by increasing the abundance of AKK bacteria in the intestine, increasing intestinal DCA levels, regulating Th17 / Treg balance, repairing the intestinal barrier, reducing LPS leakage and alleviating nerve damage, and inhibiting the inflammatory response of the gut-brain axis. This provides certain experimental evidence for the development and utilization of related traditional Chinese medicine resources.

The present invention relates to a combination comprising vitamin B2 and Lactobacillus rhamnosus and its use for improving gut health in animals and humans. It was found that a combination of vitamin B2 and Lactobacillus rhamnosus, when delivered to the large intestine, increases the abundance of beneficial Verrucomicrobia, Akkermansiaceae and Akkermansia bacteria in the intestinal tract.

The invention relates to the technical field of biological medicine, and discloses a short-chain fatty acid-containing menstrual blood stem cell exosome ackermania composition and application thereof, the composition is of a microsphere structure, and comprises a biological assembly composed of menstrual blood stem cell exosome and ackermania, and a microsphere skeleton containing low-methoxy pectin and trehalose. Wherein the exosome is adsorbed on the surface of metabolism-induced Ackerman's bacteria through a divalent metal cation mediated ion bridging effect. Metabolic induction is utilized to regulate and control the surface properties of bacteria, and an ion bridging technology is combined, so that the loading efficiency and the binding stability of the exosome are remarkably improved; a pectin-calcium gel network and trehalose are used for providing dual protection, so that the biological activity is maintained; and calcium butyrate is utilized to realize dual functions of structure construction and drug effect release. The composition can be used for preparing medicines for preventing or treating intestinal inflammation related diseases.

This invention belongs to the field of anti-fatigue functional food technology, specifically relating to an anti-fatigue and energizing composition containing inactivated Akkermansia myxophilus. Existing energizing products suffer from problems such as palpitations, dependence, or rebound fatigue. The composition of this invention contains inactivated Akkermansia myxophilus, guarana extract, theanine, B vitamins, and other anti-fatigue components. This invention achieves anti-fatigue, mental alertness, and improved concentration effects through the synergistic effect of intestinal health regulation and immediate energizing. The composition of this invention is stable at room temperature and can be formulated into instant powder or solid beverage.

The present invention relates to Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.

The present invention relates to a pharmaceutical composition, a food composition, a veterinary composition, and a cosmetic composition effective for preventing or treating metabolic diseases, which contain Akkermansia massiliensis, a culture or a dried product thereof. While traditional probiotics generally have an insignificant therapeutic effect on metabolic diseases, the next-generation pharmabiotic strain of the present invention is excellent in the prevention or treatment of metabolic diseases to the extent that it can be used as a new preventive and therapeutic tool.

The invention relates to a biomedical technology, and discloses application of dendrobium officinale polysaccharide in repairing intestinal injury and regulating metabolic disorder. In particular discloses application of dendrobium officinale polysaccharide in preparation of a functional product with the efficacy of improving intestinal injury, the peak molecular weight of the dendrobium officinale polysaccharide is 130000-140000 Da, and the efficacy of improving intestinal injury comprises the following steps: increasing the relative abundance of CandidatusSaccharimonas, Ileibacterium and Akkermansia, and reducing the relative abundance of Mucispirilline; the dendrobium officinale polysaccharide is applied to preparation of a functional product for regulating alpha-linolenic acid metabolism, preparation of a functional product for regulating nucleotide metabolism and preparation of a functional product for regulating ubiquinone biosynthesis. And the method has important significance on a conversion path of development of functional foods / medicines and other products of the dendrobium officinale polysaccharides.

The application provides a composition for promoting growth of Akkermansia and application, the composition comprises colostrum basic protein, beta-glucan and 2'-fucosyllactose, wherein, in the composition, the concentration ratio of the colostrum basic protein, beta-glucan and 2'-fucosyllactose is (0.025-0.3):(0.03-0.15):(0.6-2.5). The composition can fully meet the nutritional requirements of Akkermansia bacteria, especially mucinophilic Akkermansia bacteria, can effectively promote the growth of Akkermansia bacteria, can be used for culturing Akkermansia bacteria in vitro, and can promote the growth of mucinophilic Akkermansia bacteria in human intestinal tract, increase the potential probiotic Akkermansia bacteria in the intestinal tract, and improve intestinal health.

The application belongs to the technical field of biological medicine, and relates to application of mucinophilic Akkermansia in preparation of a medicine for improving and / or treating Parkinson's disease with depression, the application applies the mucinophilic Akkermansia to the clinical comorbidity scene of Parkinson's disease with depression, and the curative effect of the bacteria in improving the behavior of PD with depression is verified in multiple PD animal models and depression-related mouse models. The application further discloses that the mucinophilic Akkermansia improves the depression-like behavior under the background of aging, and the mucinophilic Akkermansia has different regulating effects on the peripheral and central 5-HT systems for different genetic backgrounds, which provides a theoretical basis for precise intervention targeting different PD subtypes, and it is clear that the mucinophilic Akkermansia plays a role in improving the depression-like behavior by remodeling the intestinal flora, which provides a new microbial target for treating PD depression targeting the metabolites of the flora.

The invention belongs to the field of biological detection, and particularly relates to a specific monoclonal antibody of AKK bacterium functional protein Amuc1100, a kit and a detection method and application thereof. The antibody pair is a 3E10 monoclonal antibody and a 2F7 monoclonal antibody, amino acid sequences of variable regions of a heavy chain and a light chain of the 3E10 are SEQ ID NO.2 and SEQ ID NO.4, and amino acid sequences of variable regions of a light chain of the 3E10 are SEQ ID NO.6 and SEQ ID NO.8. The antibody is strong in pairing specificity and high in affinity, colloidal gold rapid detection and a double-antibody sandwich ELISA quantitative detection kit constructed based on the antibody respectively realize rapid screening and accurate quantification of Amuc1100 protein, the detection linearity is good, the precision is high, and the accuracy is excellent; the method can be used for protein detection in mucus Ackerman bacteria and quality control and activity evaluation of related probiotic preparations, and provides key technical support for related basic research and industrial application.

The application provides a composition for promoting growth of Akkermansia and application thereof, and the composition comprises milk fat globule membrane, colostrum basic protein and lacto-N-neotetraose, wherein the concentration ratio of the milk fat globule membrane, the colostrum basic protein and the lacto-N-neotetraose in the composition is (0.1-2):(0.025-0.3):(0.2-0.8). The composition can fully meet the nutritional requirements of Akkermansia bacteria, especially mucinophilic Akkermansia bacteria, can effectively promote the growth of Akkermansia bacteria, can be used for culturing Akkermansia bacteria in vitro, and can promote the growth of mucinophilic Akkermansia bacteria in the human intestinal tract, increase the potential probiotic Akkermansia bacteria in the intestinal tract, and improve intestinal health.

This invention discloses a combination drug of Akkermansia and an EET homologue and its uses, relating to the field of biomedical technology. Specifically, the combination drug of this invention comprises: A1) a first active ingredient, the first active ingredient comprising Akkermansia myxophilus; and A2) a second active ingredient, the second active ingredient comprising at least one of 14,15-epoxyeicosatetrienoic acid (14,15-EET) or an isomer of 14,15-epoxyeicosatetrienoic acid, a pharmaceutically acceptable salt, an ester, or a prodrug. The combination drug of this invention exhibits excellent anti-inflammatory and anti-tumor effects in LPS-induced inflammation models and LLC subcutaneous tumor models. The synergistic index SI > 1 calculated using the Bliss independent model indicates a good synergistic effect, and it can be used for the prevention, treatment, and prognostic improvement of non-small cell lung cancer.

The invention belongs to the technical field of nutritional compositions and biological medicines, and particularly relates to a composition with a liver protection effect as well as a preparation method, application and a product thereof. The composition disclosed by the invention is prepared from Akkermania muciniphila and a globe artichoke extract, wherein the weight ratio of the Akkermania muciniphila to the globe artichoke extract is (1 to 8) to (1.6 to 10). The composition disclosed by the invention has a protection effect on various liver injuries such as alcoholic liver injury, chemical liver injury and non-alcoholic fatty liver injury, is obviously superior to a single bacterial preparation, a single globe artichoke extract and an existing conventional liver protection product, and can effectively reduce the levels of ALT and AST in serum, reduce liver fat deposition, inhibit liver inflammatory response and realize a liver protection effect.

This invention belongs to the field of probiotic screening and application technology, specifically relating to a strain of *Lactobacillus paracasei* and its application in the prevention and treatment of colonic polyps and colon cancer. The *Lactobacillus paracasei*, named *Lactobacillus paracasei* V85, was deposited on January 15, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, China, with accession number CCTCC NO: M2026124. The *Lactobacillus paracasei* V85 provided by this invention is sensitive to common antibiotics and has good biosafety; it possesses strong antioxidant function and a strong inhibitory effect on hemolytic streptococci; it can produce a strong agglutination effect with hemolytic streptococci, which is beneficial for inhibiting the colonization of hemolytic streptococci in the intestine, reducing the risk of colonic polyps and colon cancer caused by hemolytic streptococci, and can promote the proliferation of *Akkermansia myxophilus*. It can be used to prevent and treat colonic polyps and colon cancer caused by hemolytic streptococci, and has broad application prospects.

This article provides a system and method for the efficient and high-yield fermentation and production of Akkermansia mucin using plant-derived mucin, as well as for encapsulation to improve stability.